Metabotropic glutamate receptors as novel targets for anxiety and stress disorders

@article{Swanson2005MetabotropicGR,
  title={Metabotropic glutamate receptors as novel targets for anxiety and stress disorders},
  author={Chad J. Swanson and Mark G. Bures and Michael P Johnson and A. -M. Linden and James A. Monn and Darryle D. Schoepp},
  journal={Nature Reviews Drug Discovery},
  year={2005},
  volume={4},
  pages={131-144}
}
Anxiety and stress disorders are the most commonly occurring of all mental illnesses, and current treatments are less than satisfactory. So, the discovery of novel approaches to treat anxiety disorders remains an important area of neuroscience research. Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system, and G-protein-coupled metabotropic glutamate (mGlu) receptors function to regulate excitability via pre- and postsynaptic mechanisms. Various mGlu… Expand
Metabotropic glutamate receptor targets for neuropsychiatric disorders
TLDR
Progress has been made with less selective agents and transgenic animal tools, suggesting that other novel approaches are on the horizon in psychiatric disorders; however, less is known about the potential role of modulating other mGlu receptors in Psychiatric disorders. Expand
Metabotropic glutamate receptors: their therapeutic potential in anxiety.
TLDR
The generation of genetically manipulated animals and recent advances in the identification of subtype-selective compounds have revealed some first insights into the therapeutic potential of this group of receptors, which constitute a new group of "drugable" targets for the treatment of various CNS disorders. Expand
Metabotropic Glutamate Receptors – Regulation of Acute and Chronic Stress-Related Behavior and Physiology
TLDR
It was shown that XAP044 is systemically active and demonstrates a wide spectrum of anti-stress, antidepressant and anxiolytic-like efficacy, strongly supporting pharmacological blockade of mGlu7 as a promising mode of action for future treatment of stress-related disorders of emotion in man. Expand
Metabotropic glutamate receptor 7: at the interface of cognition and emotion.
TLDR
Data suggest that the mGlu(7) receptor is an important regulator of glutamatergic function, of fear and aversion and cognition and thus this receptor represents an innovative therapeutic target for stress-related disorders at the interface of cognition and anxiety. Expand
Mood disorders: regulation by metabotropic glutamate receptors.
TLDR
A model is presented suggesting how the interplay of glutamate at the mGlu and at the ionotropic AMPA and NMDA receptors might account for the antidepressant-like effects of glutamatergic- and monoaminergic-based drugs affecting mood in patients. Expand
Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
TLDR
This review highlights the best studied mGluR strategies for psychiatry, based on human molecular genetics, studies in animal models and preliminary clinical trials, and describes the potential value of mGLUR2 and mGlamR5 agonists and positive allosteric modulators for the treatment of schizophrenia. Expand
Metabotropic Approaches to Anxiety
TLDR
The amygdala is the structure integrating the behaviors connected with fear and anxiety, and the schema of amygdalar nuclei is shown together with the placement of mGu receptors in that structure, as the mechanisms responsible for the antianxiety actions of specific mGlu receptors ligands are explained. Expand
Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs.
TLDR
Data has been accumulated, indicating that antagonists of group II mGlu receptors have an antidepressant potential and ligands of these receptors, both agonists and antagonists, may have an anxiolytic-like and antidepressant-like potential. Expand
Chapter 4.4 The glutamatergic system as a potential therapeutic target for the treatment of anxiety disorders
TLDR
Clinical validation of the anxiolytic effects derived from preclinical models is now warranted, and the availability of genetically modified mice is also adding to the armamentarium, researchers have to dissect the role of glutamate in brain circuits relevant to anxiety. Expand
Glutamatergic Modulators for the Treatment of Major Depressive Disorder: Metabotropic Glutamate Receptors
TLDR
The bulk of data at present provides compelling evidence that mGLU5 and mGlu2/3 receptors are principal protein targets for drug discovery, and there is hope for new medicines for the devastating and life-threatening diseases of mood that affect large segments of the world community. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 150 REFERENCES
LY354740, an mGlu2/3 Receptor Agonist as a Novel Approach to Treat Anxiety/Stress
TLDR
Early clinical results with LY354740 have demonstrated safety and efficacy in a human anxiety model (panic provocation induced by CO 2 challenge), and data indicate mGlu2/3 receptor agonists such as LY 354740 represent a promising new approach for treatment of anxiety and stress-related disorders in humans. Expand
Antidepressant and anxiolytic‐like effects in mice lacking the group III metabotropic glutamate receptor mGluR7
TLDR
Analysis of behavioural profiles of mice with a targeted deletion of the gene for mGluR7 in animal models of depression and anxiety and analysis of locomotor activity in a novel environment suggest that mGLUR7 may play a pivotal role in mechanisms that regulate behavioural responses to aversive states. Expand
Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders.
TLDR
Clinical assessment of several compounds is currently underway, with antidepressant efficacy confirmed in double-blind, placebo-controlled trials of tachykinin NK(1) (substance P) receptor antagonists, and preliminary evidence of antidepressant activity in an open-label trial of a CRF(1] receptor antagonist. Expand
Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models
TLDR
The above results indicate that agonists of group II mGlu receptors may play a role in the therapy of anxiety and/or drug-dependence states. Expand
Non-peptidic CRF1 receptor antagonists for the treatment of anxiety, depression and stress disorders.
TLDR
The present review focuses on the potential of non-peptidic antagonists of the CRF(1) receptor subtype as a novel therapeutic approach for the treatment of anxiety and depression and examines a link between hyperactive CRF pathways and anxiogenic and depressive-like symptoms. Expand
Non-peptidic CRF1 receptor antagonists for the treatment of anxiety, depression and stress disorders.
TLDR
The present review focuses on the potential of non-peptidic antagonists of the CRF(1) receptor subtype as a novel therapeutic approach for the treatment of anxiety and depression. Expand
Novel functions for subtypes of metabotropic glutamate receptors
  • D. Schoepp
  • Biology, Medicine
  • Neurochemistry International
  • 1994
TLDR
Basic knowledge of the role of specific mGluRs in CNS function and pathologies will further expand in the near future, providing the framework for the discovery of novel pharmacological approaches to modulate excitatory amino acid neuronal transmission. Expand
Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system.
  • D. Schoepp
  • Biology, Medicine
  • The Journal of pharmacology and experimental therapeutics
  • 2001
TLDR
Gi-coupled mGlu receptors also may exist on presynaptic elements of neighboring gamma-aminobutyric acid neurons where they play a role in heterosynaptic suppressions of GABA release, suggesting that these receptors may have evolved to monitor glutamate that has "spilled out of the synapse". Expand
Increased anxiety-related behavior in mice deficient for metabotropic glutamate 8 (mGlu8) receptor
TLDR
It is reported that naïve mGlu8 receptor-deficient mice showed increased anxiety-related behavior in the elevated plus maze in low illumination conditions (red light), suggesting that mGLU8 receptor may play a role in responses to novel stressful environment. Expand
A Role for Noradrenergic Transmission in the Actions of Phencyclidine and the Antipsychotic and Antistress Effects of mGlu2/3 Receptor Agonists
TLDR
Data support a role for noradrenergic neurotransmission in the actions of drugs such as phencyclidine and suggest that stress pathways associated with these drugs can be normalized by mGlu2/3 receptor activation. Expand
...
1
2
3
4
5
...